Dr. Konstantinos Petritis is a bioanalytical chemist on a mission.
In the last 10 years, biomarker discovery efforts have failed to produce an FDA-approved biomarker that was discovered and validated through proteomics.
He thinks the day of discovery and validation is almost here.
Dr. Petritis is the first Head of the Center for Proteomics at The Translational Geonomics Research Institute (TGen), Pheonix, Arizona. The Center for Proteomics is one of the focal points in a biomarker development alliance between TGen, Arizona State University’s Biodesign Institute and Seattle’s Fred Hutchinson Cancer Research Center. The goal of the alliance is to integrate the biomarkers into the clinic and enable specifically targeted treatments for individual patients afflicted with cancer and other debilitating conditions. The Center for Proteomics is a branch of the alliance involved in studying proteins and the role they play in disease.
Committed to discovering and validating these critical biomarkers, Dr. Petritis oversees a state-of-the-art laboratory featuring the latest in mass spectrometry equipment, including the Waters Synapt G2 and multiple Waters Xevo TQ triple quadrupole mass spectrometers, each equipped with Waters 1D and 2D nanoACQUITY UPLC separation systems. These mass spectrometers facilitate the discovery and validation of protein biomarker candidates across large populations of patient samples.
Prior to his appointment at TGen, Dr. Petritis was a senior research scientist at the Pacific Northwest National Laboratory in Richland, Wash., working in the Biological Separations and Mass Spectrometry/Proteomics group at PNNL’s Environmental Molecular Sciences Laboratory, a branch of the Office of Science of the U.S. Department of Energy. He has more than 40 peer-reviewed publications related to biomarker discovery, proteomics, newborn screening, high-throughput sample preparation processes for biological samples, increasing protein identification confidence, and development and validation of bioanalytical methods. In addition, he has more than 100 conference communications and three patents.
Dr. Petritis has bright hopes for what the Center for Proteomics can accomplish in the future. "I know the dream of personalized medicine is nearing reality, when protein biomarkers will revolutionize medical diagnosis and prognosis through early disease detection, therapy monitoring, and matching the right patient to the right drug. We are ushering in this new era of healthcare with innovative technologies and platforms that harness the power of protein-based biomarkers.”